west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "吴飞翔" 2 results
  • Effectiveness and Safety of Implanting Sustained-Release 5-Fluorouracil during Hepatectomy for Primary Liver Cancer: A Systematic Review

    Objective To systematically review the effectiveness and safety of implanting sustained-release 5-fluorouracil during hepatectomy in patients with primary liver cancer (PLC). Methods We electronically searched the following databases including CENTRAL, MEDLINE, EMbase, WanFang Data, CBM, CNKI and VIP to collect randomized controlled trials (RCTs) on the effectiveness and safety of implanting sustained-release 5-fluorouracil during hepatectomy vs. hepatectomy alone for PLC from inception to October, 2012. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data and assessed the quality of the included studies. Then, meta-analysis was performed using RevMan 5.0 software. Results A total of 6 RCTs involving 951 patients were included. The results of meta-analysis showed that, implanting sustained-release 5-fluorouracil during hepatectomy significantly decreased the total recurrence rates of 1-year and 3-year (1 year: RR=0.48, 95%CI 0.36 to 0.65, Plt;0.000 01; 3 years: RR=0.69, 95%CI 0.50 to 0.96, P=0.03). However, the two groups were alike in decreasing the surem levels of AFP. Besides, the commonly-seen adverse reaction of implanting sustained-release 5-fluorouracil during hepatectomy included abdominal pain and bile leakage. Conclusion Implanting sustained-release 5-fluorouracil during hepatectomy can decrease the 1-year and 3-year recurrence rates of PLC patients, especially for HCC at the early stage. But this conclusion should be interpreted with caution and needs more strictly-designed RCTs with large sample size and enough long follow-up to verify.

    Release date: Export PDF Favorites Scan
  • 乳腺癌患者手术前后血浆可溶性P选择素的检测及意义△

    可溶性P选择素可抑制多形核中性粒细胞通过整合素CD11b与血管内皮细胞粘附,有明显的控制炎症的作用[1],也可介导某些肿瘤细胞与内皮细胞的粘附[2],与肿瘤的发展和转移有关。为探讨血浆可溶性P选择素水平在乳腺癌患者手术前后的变化及意义,我们检测了42例乳腺癌患者手术前后血浆可溶性P选择素水平,现报道如下。1资料与方法正常对照组36例,男女各18例,年龄23~55岁,平均37.6岁,系健康体检者,于早晨取空腹静脉血。乳腺癌组42例,年龄27~68岁,平均47.6岁,均为临床Ⅱ期患者,并行根治性手术,其中行乳腺癌根治术15例,乳腺癌改良根治术27例。组织学类型: 单纯癌29例,浸润性导管癌5例,髓样癌3例,硬癌3例,粘液腺癌2例。分别于术前1 d、术后第1 d、15 d和30 d早晨取空腹静脉血,应用可溶性P选择素ELISA试剂盒(苏州医学院血栓病研究所提供)检测血浆可溶性P选择素。所得数据用±s表示,用t检验和方差分析进行组间比较。

    Release date:2016-08-28 05:10 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content